BCIQ Profiles

Company Profile Report
1113 chmps
BioCentury & Getty Images

Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

Nov 14, 2020 | 3:23 AM GMT

Among CHMP’s monthly roundup of opinions was an MAA withdrawal for BioMarin’s hemophilia gene therapy linked to EMA concerns about safety and

Read the full 445 word article

How to gain access

Continue reading with a
two-week free trial.